Proctor & Gamble Australia - Vicks products

Published in the Commonwealth of Australia Gazette No. GN 1, 13 January 2010

THERAPEUTIC GOODS ACT 1989

I, CRAIG DAVIES, Director - Advertising and Export Section, Office of Non-Prescription Medicines, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health and Ageing for the purposes of Section 42DF(1) of the Therapeutic Goods Act 1989, give notice that the restricted representations described in paragraph (a) below, have been approved for use in advertisements directed to consumers, for the products listed in paragraph (b) provided the conditions identified in paragraph (c) are met:

1. Representations to the effect that advertisements to consumers for the goods described in paragraph (b) may refer to:
   1. "Every year, over two million children in developing countries die from pneumonia, a complication of measles which is a preventable disease" and "the complications of measles, like pneumonia, are still the biggest killer of children under five in developing countries"; and
   2. "via measles immunisation which helps reduce the incidence of pneumonia as a complication of measles in children in developing countries"
2. Vicks Vaporub (AUST R 61019)
   Vicks Inhaler (AUST R 10293)
   Vicks Vaporub Cream (AUST R 143951)
   Vicks Cough Syrup for Chesty Cough (AUST R 74809)
   Vicks F44 Chesty (AUST R 91691)
   Vicks Cough Syrup Honey Flavour for Dry Cough (AUST R 134301)
   Vicks Cough Syrup Honey Flavour for Chesty Cough (AUST R 133115)
   Vicks Cough Lozenge Honey Flavour for Dry Cough (AUST R 143442)
   Vicks Vapodrops Original Menthol (AUST L 80099)
   Vicks Vapodrops Butter Menthol (AUST L 80100)
   Vicks Vapodrops Blue Peppermint (AUST L 80101)
   Vicks Vapodrops Liquicentres (AUST L 131287)
   Vicks Vapodrops Honey Fresh (AUST L 139972)
   Vicks First Defence (ARTG #128566)
   
   sponsored by Proctor & Gamble Australia Pty Ltd
3. Subject to the conditions that:
   1. all references to "measles immunisation" are limited to being clearly associated with the Vicks "Road to Relief" cause-related program;
   2. all uses of "measles" and "pneumonia" must be co-referenced in advertisements in a manner which makes it clear that the latter is a complication of the former;
   3. all references to the effects of "measles", including deaths attributed to "pneumonia" must be clearly presented in terms of occurrence in developing countries only;
   4. references to "pneumonia" must not be given undue prominence in advertisements;
   5. all advertisements must include the following statement, prominently displayed – "Vicks is not for the treatment of pneumonia"; and
   6. the approved representations may only be used for the duration of the Vicks "Road to Relief " cause-related program.

Dated this 17th day of December 2009

CRAIG DAVIES
Delegate of the Secretary to the Department of Health and Ageing